Figure 1. Kaplan-meier Plot Displaying Estimated Probability Of Remaining Recurrence-free Over Time In The Observational Study 4 Among Joints That Were Successfully Treated In A Previous Study (Xiaflex 1)
Xiaflex Kit
Product Images NDC 66887-003
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Xiaflex (NDC 66887-003). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Endo Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Principal Display Panel – Single-pack Carton (Xiaflex 10)
Not available. The text appears to be mostly random characters and doesn't form a coherent description.*
Figure 2. Mean Percent Change In Penile Curvature Deformity – Study 1 (Xiaflex 2)
Figure 3. Mean Percent Change In Penile Curvature Deformity – Study 2 (Xiaflex 3)
This appears to be a chart displaying the mean percentage change in penile curvature deformity for a treatment called XIAFLEX versus a placebo. The chart includes five different treatment periods, labeled by week number. However, the text before the chart appears to be gibberish and not readable.*
Figure 4. Mean Change In Patient-reported Peyronie’s Disease Bother Domain Score – Study 1 (Xiaflex 4)
This is a chart that displays the mean change in the patient-reported PD Bother Domain Score for two treatments, Gileck and XIAFLEX, at two follow-up intervals, Week 24 and Week 52. The chart suggests that XIAFLEX results in less bother for patients compared to a placebo.*
Figure 5. Mean Change In Patient-reported Peyronie’s Disease Bother Domain Score – Study 2 (Xiaflex 5)
This appears to be a table or graph comparing the impact of a treatment (potentially XIAFLEX) to a placebo on the patient-reported PD (Peyronie's disease) bother domain score. The score is tracked over a 52-week follow-up period and shows less bother for the treatment group (possibly Gileck) compared to the placebo group. The initial score for the treatment group may have been 1 and the initial score for the placebo group may have been 0.*
Figure A (Xiaflex 6)
Figure B (Xiaflex 7)
Principal Display Panel – 3 mL Vial, Sterile Diluent (Xiaflex 8)
This is a description of a sterile diluent used for the reconstitution of XIAFLEX, a medication used in the treatment of Peyronie's disease and Dupuytren's contracture. The diluent contains 0.3 mg/mL of calcium chloride dihydrate in 0.9% sodium chloride. It comes in a 3ml container and is distributed by Endo Pharmaceuticals Inc. based in Malvern, PA. This product is only available by prescription.*
Principal Display Panel – 0.9 mg Vial, Xiaflex For Injection (Xiaflex 9)
This is a description of a medication called XIAFLEX, which contains 0.9 mg of collagenase clostridium histolyticum per vial. The medication is distributed by Endo Pharmaceuticals Inc. in Malvern, PA with manufacturing done by Auxilium Pharmaceuticals, LLC. It is only available through a prescription, indicated by "Rx Only" on the package. The product is identified by the National Drug Code (NDC) number 66887-003-01 and the lot number is 123724.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
